nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—Citalopram—ABCB1—esophageal cancer	0.00561	1	CrCbGaD
Escitalopram—Abdominal discomfort—Capecitabine—esophageal cancer	0.000797	0.00111	CcSEcCtD
Escitalopram—Hepatic failure—Methotrexate—esophageal cancer	0.000796	0.00111	CcSEcCtD
Escitalopram—Pancytopenia—Capecitabine—esophageal cancer	0.000789	0.0011	CcSEcCtD
Escitalopram—Erythema—Cisplatin—esophageal cancer	0.000785	0.00109	CcSEcCtD
Escitalopram—Malnutrition—Cisplatin—esophageal cancer	0.000785	0.00109	CcSEcCtD
Escitalopram—Dysuria—Capecitabine—esophageal cancer	0.000777	0.00108	CcSEcCtD
Escitalopram—Renal failure acute—Methotrexate—esophageal cancer	0.000775	0.00108	CcSEcCtD
Escitalopram—Flatulence—Cisplatin—esophageal cancer	0.000774	0.00107	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000772	0.00107	CcSEcCtD
Escitalopram—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000759	0.00105	CcSEcCtD
Escitalopram—Weight increased—Capecitabine—esophageal cancer	0.000756	0.00105	CcSEcCtD
Escitalopram—Visual disturbance—Methotrexate—esophageal cancer	0.000755	0.00105	CcSEcCtD
Escitalopram—Muscle spasms—Cisplatin—esophageal cancer	0.000755	0.00105	CcSEcCtD
Escitalopram—Weight decreased—Capecitabine—esophageal cancer	0.000752	0.00104	CcSEcCtD
Escitalopram—Hyperglycaemia—Capecitabine—esophageal cancer	0.00075	0.00104	CcSEcCtD
Escitalopram—Pneumonia—Capecitabine—esophageal cancer	0.000745	0.00103	CcSEcCtD
Escitalopram—Infestation NOS—Capecitabine—esophageal cancer	0.000741	0.00103	CcSEcCtD
Escitalopram—Infestation—Capecitabine—esophageal cancer	0.000741	0.00103	CcSEcCtD
Escitalopram—Vision blurred—Cisplatin—esophageal cancer	0.00074	0.00103	CcSEcCtD
Escitalopram—Depression—Capecitabine—esophageal cancer	0.000739	0.00103	CcSEcCtD
Escitalopram—Tremor—Cisplatin—esophageal cancer	0.000736	0.00102	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000735	0.00102	CcSEcCtD
Escitalopram—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00073	0.00101	CcSEcCtD
Escitalopram—Lethargy—Methotrexate—esophageal cancer	0.00073	0.00101	CcSEcCtD
Escitalopram—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00073	0.00101	CcSEcCtD
Escitalopram—Ill-defined disorder—Cisplatin—esophageal cancer	0.000729	0.00101	CcSEcCtD
Escitalopram—Myocardial infarction—Capecitabine—esophageal cancer	0.000726	0.00101	CcSEcCtD
Escitalopram—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000726	0.00101	CcSEcCtD
Escitalopram—Anaemia—Cisplatin—esophageal cancer	0.000726	0.00101	CcSEcCtD
Escitalopram—Jaundice—Capecitabine—esophageal cancer	0.000722	0.001	CcSEcCtD
Escitalopram—Stomatitis—Capecitabine—esophageal cancer	0.000722	0.001	CcSEcCtD
Escitalopram—Conjunctivitis—Capecitabine—esophageal cancer	0.00072	0.001	CcSEcCtD
Escitalopram—Urinary tract infection—Capecitabine—esophageal cancer	0.00072	0.001	CcSEcCtD
Escitalopram—Osteoarthritis—Methotrexate—esophageal cancer	0.000716	0.000994	CcSEcCtD
Escitalopram—Malaise—Cisplatin—esophageal cancer	0.000708	0.000984	CcSEcCtD
Escitalopram—Haematuria—Capecitabine—esophageal cancer	0.000706	0.000981	CcSEcCtD
Escitalopram—Leukopenia—Cisplatin—esophageal cancer	0.000703	0.000976	CcSEcCtD
Escitalopram—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000701	0.000973	CcSEcCtD
Escitalopram—Epistaxis—Capecitabine—esophageal cancer	0.000699	0.000971	CcSEcCtD
Escitalopram—Agranulocytosis—Capecitabine—esophageal cancer	0.000691	0.00096	CcSEcCtD
Escitalopram—Irritability—Methotrexate—esophageal cancer	0.000683	0.000949	CcSEcCtD
Escitalopram—Convulsion—Cisplatin—esophageal cancer	0.000681	0.000945	CcSEcCtD
Escitalopram—Mood swings—Methotrexate—esophageal cancer	0.000678	0.000942	CcSEcCtD
Escitalopram—Bradycardia—Capecitabine—esophageal cancer	0.000677	0.00094	CcSEcCtD
Escitalopram—Ataxia—Methotrexate—esophageal cancer	0.000673	0.000935	CcSEcCtD
Escitalopram—Myalgia—Cisplatin—esophageal cancer	0.000669	0.000929	CcSEcCtD
Escitalopram—Haemoglobin—Capecitabine—esophageal cancer	0.000669	0.000928	CcSEcCtD
Escitalopram—Rhinitis—Capecitabine—esophageal cancer	0.000667	0.000926	CcSEcCtD
Escitalopram—Anxiety—Cisplatin—esophageal cancer	0.000666	0.000925	CcSEcCtD
Escitalopram—Haemorrhage—Capecitabine—esophageal cancer	0.000665	0.000924	CcSEcCtD
Escitalopram—Hepatitis—Capecitabine—esophageal cancer	0.000665	0.000924	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000664	0.000922	CcSEcCtD
Escitalopram—Hypoaesthesia—Capecitabine—esophageal cancer	0.000662	0.000919	CcSEcCtD
Escitalopram—Liver function test abnormal—Methotrexate—esophageal cancer	0.000661	0.000918	CcSEcCtD
Escitalopram—Discomfort—Cisplatin—esophageal cancer	0.000661	0.000918	CcSEcCtD
Escitalopram—Pharyngitis—Capecitabine—esophageal cancer	0.00066	0.000917	CcSEcCtD
Escitalopram—Urinary tract disorder—Capecitabine—esophageal cancer	0.000657	0.000912	CcSEcCtD
Escitalopram—Oedema peripheral—Capecitabine—esophageal cancer	0.000655	0.00091	CcSEcCtD
Escitalopram—Connective tissue disorder—Capecitabine—esophageal cancer	0.000654	0.000908	CcSEcCtD
Escitalopram—Urethral disorder—Capecitabine—esophageal cancer	0.000652	0.000905	CcSEcCtD
Escitalopram—Breast disorder—Methotrexate—esophageal cancer	0.000647	0.000898	CcSEcCtD
Escitalopram—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000645	0.000895	CcSEcCtD
Escitalopram—Anaphylactic shock—Cisplatin—esophageal cancer	0.000641	0.00089	CcSEcCtD
Escitalopram—Oedema—Cisplatin—esophageal cancer	0.000641	0.00089	CcSEcCtD
Escitalopram—Visual impairment—Capecitabine—esophageal cancer	0.000641	0.00089	CcSEcCtD
Escitalopram—Infection—Cisplatin—esophageal cancer	0.000637	0.000884	CcSEcCtD
Escitalopram—Erythema multiforme—Capecitabine—esophageal cancer	0.000629	0.000873	CcSEcCtD
Escitalopram—Nervous system disorder—Cisplatin—esophageal cancer	0.000629	0.000873	CcSEcCtD
Escitalopram—Thrombocytopenia—Cisplatin—esophageal cancer	0.000628	0.000872	CcSEcCtD
Escitalopram—Tachycardia—Cisplatin—esophageal cancer	0.000626	0.000869	CcSEcCtD
Escitalopram—Skin disorder—Cisplatin—esophageal cancer	0.000623	0.000865	CcSEcCtD
Escitalopram—Eye disorder—Capecitabine—esophageal cancer	0.000622	0.000863	CcSEcCtD
Escitalopram—Tinnitus—Capecitabine—esophageal cancer	0.00062	0.000861	CcSEcCtD
Escitalopram—Hyperhidrosis—Cisplatin—esophageal cancer	0.00062	0.000861	CcSEcCtD
Escitalopram—Asthma—Methotrexate—esophageal cancer	0.000619	0.000859	CcSEcCtD
Escitalopram—Cardiac disorder—Capecitabine—esophageal cancer	0.000617	0.000857	CcSEcCtD
Escitalopram—Flushing—Capecitabine—esophageal cancer	0.000617	0.000857	CcSEcCtD
Escitalopram—Eosinophilia—Methotrexate—esophageal cancer	0.000612	0.000851	CcSEcCtD
Escitalopram—Anorexia—Cisplatin—esophageal cancer	0.000611	0.000849	CcSEcCtD
Escitalopram—Pancreatitis—Methotrexate—esophageal cancer	0.000607	0.000842	CcSEcCtD
Escitalopram—Angiopathy—Capecitabine—esophageal cancer	0.000603	0.000838	CcSEcCtD
Escitalopram—Immune system disorder—Capecitabine—esophageal cancer	0.000601	0.000834	CcSEcCtD
Escitalopram—Mediastinal disorder—Capecitabine—esophageal cancer	0.000599	0.000832	CcSEcCtD
Escitalopram—Hypotension—Cisplatin—esophageal cancer	0.000599	0.000832	CcSEcCtD
Escitalopram—Chills—Capecitabine—esophageal cancer	0.000597	0.000829	CcSEcCtD
Escitalopram—Arrhythmia—Capecitabine—esophageal cancer	0.000594	0.000825	CcSEcCtD
Escitalopram—Abdominal discomfort—Methotrexate—esophageal cancer	0.000593	0.000824	CcSEcCtD
Escitalopram—Alopecia—Capecitabine—esophageal cancer	0.000588	0.000816	CcSEcCtD
Escitalopram—Pancytopenia—Methotrexate—esophageal cancer	0.000587	0.000816	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000584	0.000811	CcSEcCtD
Escitalopram—Mental disorder—Capecitabine—esophageal cancer	0.000583	0.000809	CcSEcCtD
Escitalopram—Erythema—Capecitabine—esophageal cancer	0.000579	0.000804	CcSEcCtD
Escitalopram—Malnutrition—Capecitabine—esophageal cancer	0.000579	0.000804	CcSEcCtD
Escitalopram—Dysuria—Methotrexate—esophageal cancer	0.000578	0.000803	CcSEcCtD
Escitalopram—Paraesthesia—Cisplatin—esophageal cancer	0.000576	0.000799	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000575	0.000798	CcSEcCtD
Escitalopram—Dyspnoea—Cisplatin—esophageal cancer	0.000572	0.000794	CcSEcCtD
Escitalopram—Flatulence—Capecitabine—esophageal cancer	0.000571	0.000792	CcSEcCtD
Escitalopram—Erectile dysfunction—Methotrexate—esophageal cancer	0.00057	0.000791	CcSEcCtD
Escitalopram—Dysgeusia—Capecitabine—esophageal cancer	0.000567	0.000787	CcSEcCtD
Escitalopram—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000565	0.000784	CcSEcCtD
Escitalopram—Back pain—Capecitabine—esophageal cancer	0.00056	0.000778	CcSEcCtD
Escitalopram—Decreased appetite—Cisplatin—esophageal cancer	0.000557	0.000774	CcSEcCtD
Escitalopram—Muscle spasms—Capecitabine—esophageal cancer	0.000557	0.000773	CcSEcCtD
Escitalopram—Pneumonia—Methotrexate—esophageal cancer	0.000555	0.00077	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000553	0.000769	CcSEcCtD
Escitalopram—Infestation NOS—Methotrexate—esophageal cancer	0.000552	0.000766	CcSEcCtD
Escitalopram—Infestation—Methotrexate—esophageal cancer	0.000552	0.000766	CcSEcCtD
Escitalopram—Depression—Methotrexate—esophageal cancer	0.00055	0.000764	CcSEcCtD
Escitalopram—Pain—Cisplatin—esophageal cancer	0.000548	0.000761	CcSEcCtD
Escitalopram—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000547	0.000759	CcSEcCtD
Escitalopram—Vision blurred—Capecitabine—esophageal cancer	0.000546	0.000758	CcSEcCtD
Escitalopram—Tremor—Capecitabine—esophageal cancer	0.000542	0.000753	CcSEcCtD
Escitalopram—Stomatitis—Methotrexate—esophageal cancer	0.000538	0.000747	CcSEcCtD
Escitalopram—Ill-defined disorder—Capecitabine—esophageal cancer	0.000537	0.000746	CcSEcCtD
Escitalopram—Conjunctivitis—Methotrexate—esophageal cancer	0.000536	0.000745	CcSEcCtD
Escitalopram—Anaemia—Capecitabine—esophageal cancer	0.000535	0.000743	CcSEcCtD
Escitalopram—Sweating—Methotrexate—esophageal cancer	0.000529	0.000734	CcSEcCtD
Escitalopram—Feeling abnormal—Cisplatin—esophageal cancer	0.000528	0.000734	CcSEcCtD
Escitalopram—Haematuria—Methotrexate—esophageal cancer	0.000526	0.00073	CcSEcCtD
Escitalopram—Malaise—Capecitabine—esophageal cancer	0.000522	0.000725	CcSEcCtD
Escitalopram—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000522	0.000724	CcSEcCtD
Escitalopram—Epistaxis—Methotrexate—esophageal cancer	0.00052	0.000722	CcSEcCtD
Escitalopram—Vertigo—Capecitabine—esophageal cancer	0.00052	0.000722	CcSEcCtD
Escitalopram—Syncope—Capecitabine—esophageal cancer	0.000519	0.000721	CcSEcCtD
Escitalopram—Leukopenia—Capecitabine—esophageal cancer	0.000518	0.00072	CcSEcCtD
Escitalopram—Agranulocytosis—Methotrexate—esophageal cancer	0.000515	0.000715	CcSEcCtD
Escitalopram—Palpitations—Capecitabine—esophageal cancer	0.000512	0.000711	CcSEcCtD
Escitalopram—Loss of consciousness—Capecitabine—esophageal cancer	0.000509	0.000707	CcSEcCtD
Escitalopram—Body temperature increased—Cisplatin—esophageal cancer	0.000507	0.000704	CcSEcCtD
Escitalopram—Cough—Capecitabine—esophageal cancer	0.000505	0.000702	CcSEcCtD
Escitalopram—Hypertension—Capecitabine—esophageal cancer	0.0005	0.000694	CcSEcCtD
Escitalopram—Haemoglobin—Methotrexate—esophageal cancer	0.000498	0.000691	CcSEcCtD
Escitalopram—Hepatitis—Methotrexate—esophageal cancer	0.000495	0.000688	CcSEcCtD
Escitalopram—Haemorrhage—Methotrexate—esophageal cancer	0.000495	0.000688	CcSEcCtD
Escitalopram—Myalgia—Capecitabine—esophageal cancer	0.000493	0.000685	CcSEcCtD
Escitalopram—Chest pain—Capecitabine—esophageal cancer	0.000493	0.000685	CcSEcCtD
Escitalopram—Arthralgia—Capecitabine—esophageal cancer	0.000493	0.000685	CcSEcCtD
Escitalopram—Pharyngitis—Methotrexate—esophageal cancer	0.000491	0.000682	CcSEcCtD
Escitalopram—Anxiety—Capecitabine—esophageal cancer	0.000491	0.000682	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00049	0.00068	CcSEcCtD
Escitalopram—Urinary tract disorder—Methotrexate—esophageal cancer	0.000489	0.000679	CcSEcCtD
Escitalopram—Discomfort—Capecitabine—esophageal cancer	0.000487	0.000676	CcSEcCtD
Escitalopram—Urethral disorder—Methotrexate—esophageal cancer	0.000485	0.000674	CcSEcCtD
Escitalopram—Dry mouth—Capecitabine—esophageal cancer	0.000482	0.00067	CcSEcCtD
Escitalopram—Visual impairment—Methotrexate—esophageal cancer	0.000477	0.000663	CcSEcCtD
Escitalopram—Confusional state—Capecitabine—esophageal cancer	0.000476	0.000662	CcSEcCtD
Escitalopram—Oedema—Capecitabine—esophageal cancer	0.000473	0.000656	CcSEcCtD
Escitalopram—Hypersensitivity—Cisplatin—esophageal cancer	0.000472	0.000656	CcSEcCtD
Escitalopram—Infection—Capecitabine—esophageal cancer	0.000469	0.000652	CcSEcCtD
Escitalopram—Erythema multiforme—Methotrexate—esophageal cancer	0.000468	0.00065	CcSEcCtD
Escitalopram—Shock—Capecitabine—esophageal cancer	0.000465	0.000646	CcSEcCtD
Escitalopram—Nervous system disorder—Capecitabine—esophageal cancer	0.000463	0.000644	CcSEcCtD
Escitalopram—Eye disorder—Methotrexate—esophageal cancer	0.000463	0.000643	CcSEcCtD
Escitalopram—Thrombocytopenia—Capecitabine—esophageal cancer	0.000463	0.000643	CcSEcCtD
Escitalopram—Tinnitus—Methotrexate—esophageal cancer	0.000462	0.000641	CcSEcCtD
Escitalopram—Tachycardia—Capecitabine—esophageal cancer	0.000461	0.00064	CcSEcCtD
Escitalopram—Asthenia—Cisplatin—esophageal cancer	0.00046	0.000639	CcSEcCtD
Escitalopram—Cardiac disorder—Methotrexate—esophageal cancer	0.00046	0.000638	CcSEcCtD
Escitalopram—Skin disorder—Capecitabine—esophageal cancer	0.000459	0.000637	CcSEcCtD
Escitalopram—Hyperhidrosis—Capecitabine—esophageal cancer	0.000457	0.000634	CcSEcCtD
Escitalopram—Anorexia—Capecitabine—esophageal cancer	0.00045	0.000626	CcSEcCtD
Escitalopram—Angiopathy—Methotrexate—esophageal cancer	0.000449	0.000624	CcSEcCtD
Escitalopram—Immune system disorder—Methotrexate—esophageal cancer	0.000447	0.000621	CcSEcCtD
Escitalopram—Mediastinal disorder—Methotrexate—esophageal cancer	0.000446	0.00062	CcSEcCtD
Escitalopram—Chills—Methotrexate—esophageal cancer	0.000444	0.000617	CcSEcCtD
Escitalopram—Hypotension—Capecitabine—esophageal cancer	0.000442	0.000613	CcSEcCtD
Escitalopram—Diarrhoea—Cisplatin—esophageal cancer	0.000439	0.000609	CcSEcCtD
Escitalopram—Alopecia—Methotrexate—esophageal cancer	0.000438	0.000608	CcSEcCtD
Escitalopram—Mental disorder—Methotrexate—esophageal cancer	0.000434	0.000602	CcSEcCtD
Escitalopram—Erythema—Methotrexate—esophageal cancer	0.000431	0.000599	CcSEcCtD
Escitalopram—Malnutrition—Methotrexate—esophageal cancer	0.000431	0.000599	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000431	0.000598	CcSEcCtD
Escitalopram—Insomnia—Capecitabine—esophageal cancer	0.000427	0.000594	CcSEcCtD
Escitalopram—Paraesthesia—Capecitabine—esophageal cancer	0.000424	0.000589	CcSEcCtD
Escitalopram—Dysgeusia—Methotrexate—esophageal cancer	0.000422	0.000586	CcSEcCtD
Escitalopram—Dyspnoea—Capecitabine—esophageal cancer	0.000421	0.000585	CcSEcCtD
Escitalopram—Back pain—Methotrexate—esophageal cancer	0.000417	0.000579	CcSEcCtD
Escitalopram—Dyspepsia—Capecitabine—esophageal cancer	0.000416	0.000578	CcSEcCtD
Escitalopram—Decreased appetite—Capecitabine—esophageal cancer	0.000411	0.00057	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000408	0.000567	CcSEcCtD
Escitalopram—Vomiting—Cisplatin—esophageal cancer	0.000408	0.000566	CcSEcCtD
Escitalopram—Fatigue—Capecitabine—esophageal cancer	0.000407	0.000566	CcSEcCtD
Escitalopram—Vision blurred—Methotrexate—esophageal cancer	0.000406	0.000564	CcSEcCtD
Escitalopram—Rash—Cisplatin—esophageal cancer	0.000404	0.000561	CcSEcCtD
Escitalopram—Pain—Capecitabine—esophageal cancer	0.000404	0.000561	CcSEcCtD
Escitalopram—Constipation—Capecitabine—esophageal cancer	0.000404	0.000561	CcSEcCtD
Escitalopram—Dermatitis—Cisplatin—esophageal cancer	0.000404	0.000561	CcSEcCtD
Escitalopram—Ill-defined disorder—Methotrexate—esophageal cancer	0.0004	0.000555	CcSEcCtD
Escitalopram—Anaemia—Methotrexate—esophageal cancer	0.000398	0.000553	CcSEcCtD
Escitalopram—Feeling abnormal—Capecitabine—esophageal cancer	0.000389	0.000541	CcSEcCtD
Escitalopram—Malaise—Methotrexate—esophageal cancer	0.000389	0.00054	CcSEcCtD
Escitalopram—Vertigo—Methotrexate—esophageal cancer	0.000387	0.000538	CcSEcCtD
Escitalopram—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000386	0.000537	CcSEcCtD
Escitalopram—Leukopenia—Methotrexate—esophageal cancer	0.000386	0.000536	CcSEcCtD
Escitalopram—Nausea—Cisplatin—esophageal cancer	0.000381	0.000529	CcSEcCtD
Escitalopram—Cough—Methotrexate—esophageal cancer	0.000376	0.000522	CcSEcCtD
Escitalopram—Urticaria—Capecitabine—esophageal cancer	0.000375	0.000521	CcSEcCtD
Escitalopram—Abdominal pain—Capecitabine—esophageal cancer	0.000374	0.000519	CcSEcCtD
Escitalopram—Body temperature increased—Capecitabine—esophageal cancer	0.000374	0.000519	CcSEcCtD
Escitalopram—Convulsion—Methotrexate—esophageal cancer	0.000373	0.000519	CcSEcCtD
Escitalopram—Chest pain—Methotrexate—esophageal cancer	0.000367	0.00051	CcSEcCtD
Escitalopram—Myalgia—Methotrexate—esophageal cancer	0.000367	0.00051	CcSEcCtD
Escitalopram—Arthralgia—Methotrexate—esophageal cancer	0.000367	0.00051	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000364	0.000506	CcSEcCtD
Escitalopram—Discomfort—Methotrexate—esophageal cancer	0.000363	0.000504	CcSEcCtD
Escitalopram—Confusional state—Methotrexate—esophageal cancer	0.000355	0.000493	CcSEcCtD
Escitalopram—Anaphylactic shock—Methotrexate—esophageal cancer	0.000352	0.000489	CcSEcCtD
Escitalopram—Infection—Methotrexate—esophageal cancer	0.000349	0.000485	CcSEcCtD
Escitalopram—Hypersensitivity—Capecitabine—esophageal cancer	0.000348	0.000484	CcSEcCtD
Escitalopram—Nervous system disorder—Methotrexate—esophageal cancer	0.000345	0.000479	CcSEcCtD
Escitalopram—Thrombocytopenia—Methotrexate—esophageal cancer	0.000344	0.000478	CcSEcCtD
Escitalopram—Skin disorder—Methotrexate—esophageal cancer	0.000342	0.000475	CcSEcCtD
Escitalopram—Hyperhidrosis—Methotrexate—esophageal cancer	0.00034	0.000472	CcSEcCtD
Escitalopram—Asthenia—Capecitabine—esophageal cancer	0.000339	0.000471	CcSEcCtD
Escitalopram—Anorexia—Methotrexate—esophageal cancer	0.000335	0.000466	CcSEcCtD
Escitalopram—Pruritus—Capecitabine—esophageal cancer	0.000334	0.000464	CcSEcCtD
Escitalopram—Hypotension—Methotrexate—esophageal cancer	0.000329	0.000456	CcSEcCtD
Escitalopram—Diarrhoea—Capecitabine—esophageal cancer	0.000323	0.000449	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000321	0.000445	CcSEcCtD
Escitalopram—Insomnia—Methotrexate—esophageal cancer	0.000318	0.000442	CcSEcCtD
Escitalopram—Paraesthesia—Methotrexate—esophageal cancer	0.000316	0.000439	CcSEcCtD
Escitalopram—Dyspnoea—Methotrexate—esophageal cancer	0.000314	0.000436	CcSEcCtD
Escitalopram—Somnolence—Methotrexate—esophageal cancer	0.000313	0.000434	CcSEcCtD
Escitalopram—Dizziness—Capecitabine—esophageal cancer	0.000312	0.000434	CcSEcCtD
Escitalopram—Dyspepsia—Methotrexate—esophageal cancer	0.00031	0.00043	CcSEcCtD
Escitalopram—Decreased appetite—Methotrexate—esophageal cancer	0.000306	0.000425	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000304	0.000422	CcSEcCtD
Escitalopram—Fatigue—Methotrexate—esophageal cancer	0.000303	0.000421	CcSEcCtD
Escitalopram—Pain—Methotrexate—esophageal cancer	0.000301	0.000418	CcSEcCtD
Escitalopram—Vomiting—Capecitabine—esophageal cancer	0.0003	0.000417	CcSEcCtD
Escitalopram—Rash—Capecitabine—esophageal cancer	0.000298	0.000414	CcSEcCtD
Escitalopram—Dermatitis—Capecitabine—esophageal cancer	0.000298	0.000413	CcSEcCtD
Escitalopram—Headache—Capecitabine—esophageal cancer	0.000296	0.000411	CcSEcCtD
Escitalopram—Feeling abnormal—Methotrexate—esophageal cancer	0.00029	0.000403	CcSEcCtD
Escitalopram—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000288	0.000399	CcSEcCtD
Escitalopram—Nausea—Capecitabine—esophageal cancer	0.000281	0.00039	CcSEcCtD
Escitalopram—Urticaria—Methotrexate—esophageal cancer	0.000279	0.000388	CcSEcCtD
Escitalopram—Body temperature increased—Methotrexate—esophageal cancer	0.000278	0.000386	CcSEcCtD
Escitalopram—Abdominal pain—Methotrexate—esophageal cancer	0.000278	0.000386	CcSEcCtD
Escitalopram—Hypersensitivity—Methotrexate—esophageal cancer	0.000259	0.00036	CcSEcCtD
Escitalopram—Asthenia—Methotrexate—esophageal cancer	0.000252	0.000351	CcSEcCtD
Escitalopram—Pruritus—Methotrexate—esophageal cancer	0.000249	0.000346	CcSEcCtD
Escitalopram—Diarrhoea—Methotrexate—esophageal cancer	0.000241	0.000334	CcSEcCtD
Escitalopram—Dizziness—Methotrexate—esophageal cancer	0.000233	0.000323	CcSEcCtD
Escitalopram—Vomiting—Methotrexate—esophageal cancer	0.000224	0.000311	CcSEcCtD
Escitalopram—Rash—Methotrexate—esophageal cancer	0.000222	0.000308	CcSEcCtD
Escitalopram—Dermatitis—Methotrexate—esophageal cancer	0.000222	0.000308	CcSEcCtD
Escitalopram—Headache—Methotrexate—esophageal cancer	0.00022	0.000306	CcSEcCtD
Escitalopram—Nausea—Methotrexate—esophageal cancer	0.000209	0.00029	CcSEcCtD
Escitalopram—ADRA1A—Signaling by GPCR—SST—esophageal cancer	0.0001	0.000365	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.0001	0.000365	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—GHRL—esophageal cancer	9.94e-05	0.000362	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—GHRL—esophageal cancer	9.91e-05	0.000361	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PFN1—esophageal cancer	9.9e-05	0.000361	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PFN1—esophageal cancer	9.87e-05	0.00036	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	9.85e-05	0.000359	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—GHRL—esophageal cancer	9.75e-05	0.000356	CbGpPWpGaD
Escitalopram—HRH1—G alpha (q) signalling events—PIK3CA—esophageal cancer	9.74e-05	0.000355	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PFN1—esophageal cancer	9.72e-05	0.000354	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—PIK3CA—esophageal cancer	9.71e-05	0.000354	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CA1—esophageal cancer	9.59e-05	0.000349	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC10A2—esophageal cancer	9.59e-05	0.000349	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	9.57e-05	0.000349	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—PIK3CA—esophageal cancer	9.56e-05	0.000348	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CA2—esophageal cancer	9.53e-05	0.000347	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	9.32e-05	0.00034	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HIST1H2BM—esophageal cancer	9.26e-05	0.000338	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PDE4D—esophageal cancer	9.18e-05	0.000335	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ELMO1—esophageal cancer	8.89e-05	0.000324	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ELMO1—esophageal cancer	8.87e-05	0.000323	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—TP53—esophageal cancer	8.87e-05	0.000323	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ADH7—esophageal cancer	8.86e-05	0.000323	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PLCE1—esophageal cancer	8.86e-05	0.000323	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CA2—esophageal cancer	8.77e-05	0.00032	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	8.76e-05	0.000319	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ELMO1—esophageal cancer	8.73e-05	0.000318	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GNG7—esophageal cancer	8.73e-05	0.000318	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	8.71e-05	0.000318	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKAP13—esophageal cancer	8.69e-05	0.000317	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	8.68e-05	0.000317	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKAP13—esophageal cancer	8.67e-05	0.000316	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	8.55e-05	0.000312	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKAP13—esophageal cancer	8.53e-05	0.000311	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—XIAP—esophageal cancer	8.18e-05	0.000298	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ADH7—esophageal cancer	8.15e-05	0.000297	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PLCE1—esophageal cancer	8.15e-05	0.000297	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HIST1H2BM—esophageal cancer	8.02e-05	0.000292	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	8e-05	0.000292	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PDE4D—esophageal cancer	7.95e-05	0.00029	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PDE4D—esophageal cancer	7.93e-05	0.000289	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HIST1H2BM—esophageal cancer	7.87e-05	0.000287	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PDE4D—esophageal cancer	7.8e-05	0.000284	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ADH1B—esophageal cancer	7.77e-05	0.000283	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CTNNA1—esophageal cancer	7.73e-05	0.000282	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL2—esophageal cancer	7.69e-05	0.00028	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GNG7—esophageal cancer	7.56e-05	0.000276	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GNG7—esophageal cancer	7.54e-05	0.000275	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TYMP—esophageal cancer	7.43e-05	0.000271	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GNG7—esophageal cancer	7.42e-05	0.000271	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC52A3—esophageal cancer	7.37e-05	0.000269	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—BLVRB—esophageal cancer	7.37e-05	0.000269	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP26A1—esophageal cancer	7.22e-05	0.000263	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PSME2—esophageal cancer	7.18e-05	0.000262	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PSME1—esophageal cancer	7.18e-05	0.000262	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ANXA1—esophageal cancer	7.15e-05	0.000261	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ADH1B—esophageal cancer	7.15e-05	0.000261	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—XIAP—esophageal cancer	7.09e-05	0.000258	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—XIAP—esophageal cancer	7.06e-05	0.000258	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ALOX15—esophageal cancer	7.04e-05	0.000257	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—XIAP—esophageal cancer	6.95e-05	0.000254	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SST—esophageal cancer	6.95e-05	0.000254	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TYMP—esophageal cancer	6.83e-05	0.000249	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NOTCH3—esophageal cancer	6.78e-05	0.000247	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GHRL—esophageal cancer	6.78e-05	0.000247	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTO1—esophageal cancer	6.72e-05	0.000245	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TPI1—esophageal cancer	6.72e-05	0.000245	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CTNNA1—esophageal cancer	6.7e-05	0.000244	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CTNNA1—esophageal cancer	6.68e-05	0.000244	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—FBXW7—esophageal cancer	6.67e-05	0.000243	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL2—esophageal cancer	6.66e-05	0.000243	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP26A1—esophageal cancer	6.64e-05	0.000242	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL2—esophageal cancer	6.64e-05	0.000242	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CTNNA1—esophageal cancer	6.58e-05	0.00024	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL2—esophageal cancer	6.54e-05	0.000238	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ALOX15—esophageal cancer	6.47e-05	0.000236	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ALDOB—esophageal cancer	6.44e-05	0.000235	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC10A2—esophageal cancer	6.27e-05	0.000228	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CA1—esophageal cancer	6.27e-05	0.000228	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PSME2—esophageal cancer	6.22e-05	0.000227	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PSME1—esophageal cancer	6.22e-05	0.000227	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PSME1—esophageal cancer	6.2e-05	0.000226	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PSME2—esophageal cancer	6.2e-05	0.000226	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GAPDH—esophageal cancer	6.2e-05	0.000226	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ANXA1—esophageal cancer	6.19e-05	0.000226	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTO1—esophageal cancer	6.18e-05	0.000225	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TPI1—esophageal cancer	6.18e-05	0.000225	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ANXA1—esophageal cancer	6.17e-05	0.000225	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CRABP1—esophageal cancer	6.14e-05	0.000224	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	6.11e-05	0.000223	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	6.11e-05	0.000223	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	6.08e-05	0.000222	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NOTCH2—esophageal cancer	6.08e-05	0.000222	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SST—esophageal cancer	6.03e-05	0.00022	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SST—esophageal cancer	6.01e-05	0.000219	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ALDOB—esophageal cancer	5.92e-05	0.000216	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SST—esophageal cancer	5.91e-05	0.000216	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GHRL—esophageal cancer	5.87e-05	0.000214	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOTCH3—esophageal cancer	5.87e-05	0.000214	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GHRL—esophageal cancer	5.85e-05	0.000213	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOTCH3—esophageal cancer	5.85e-05	0.000213	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GNG7—esophageal cancer	5.84e-05	0.000213	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FBXW7—esophageal cancer	5.78e-05	0.000211	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	5.76e-05	0.00021	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	5.76e-05	0.00021	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FBXW7—esophageal cancer	5.76e-05	0.00021	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CA2—esophageal cancer	5.73e-05	0.000209	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GAPDH—esophageal cancer	5.7e-05	0.000208	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	5.67e-05	0.000207	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CRABP1—esophageal cancer	5.65e-05	0.000206	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ALDH2—esophageal cancer	5.47e-05	0.0002	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	5.39e-05	0.000197	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GNG7—esophageal cancer	5.37e-05	0.000196	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ADH7—esophageal cancer	5.33e-05	0.000194	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PLCE1—esophageal cancer	5.33e-05	0.000194	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOTCH2—esophageal cancer	5.27e-05	0.000192	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	5.25e-05	0.000191	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTT1—esophageal cancer	5.21e-05	0.00019	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	5.17e-05	0.000188	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP2A6—esophageal cancer	5.15e-05	0.000188	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.13e-05	0.000187	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	5.1e-05	0.000186	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ALDH2—esophageal cancer	5.04e-05	0.000184	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ENO1—esophageal cancer	4.88e-05	0.000178	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS1—esophageal cancer	4.88e-05	0.000178	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PSME2—esophageal cancer	4.81e-05	0.000175	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PSME1—esophageal cancer	4.81e-05	0.000175	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTT1—esophageal cancer	4.79e-05	0.000175	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP2A6—esophageal cancer	4.73e-05	0.000173	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ADH1B—esophageal cancer	4.67e-05	0.00017	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	4.67e-05	0.00017	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	4.66e-05	0.00017	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	4.58e-05	0.000167	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS1—esophageal cancer	4.49e-05	0.000164	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ENO1—esophageal cancer	4.49e-05	0.000164	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMP—esophageal cancer	4.47e-05	0.000163	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SMAD4—esophageal cancer	4.42e-05	0.000161	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PSME1—esophageal cancer	4.42e-05	0.000161	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PSME2—esophageal cancer	4.42e-05	0.000161	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	4.41e-05	0.000161	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP26A1—esophageal cancer	4.34e-05	0.000158	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	4.34e-05	0.000158	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALOX15—esophageal cancer	4.23e-05	0.000154	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.2e-05	0.000153	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	4.18e-05	0.000152	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP1B1—esophageal cancer	4.15e-05	0.000151	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TPI1—esophageal cancer	4.04e-05	0.000147	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTO1—esophageal cancer	4.04e-05	0.000147	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KDR—esophageal cancer	3.99e-05	0.000146	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP19A1—esophageal cancer	3.9e-05	0.000142	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.87e-05	0.000141	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP1B1—esophageal cancer	3.82e-05	0.000139	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	3.76e-05	0.000137	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.73e-05	0.000136	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.69e-05	0.000135	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HIF1A—esophageal cancer	3.62e-05	0.000132	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	3.61e-05	0.000132	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP19A1—esophageal cancer	3.59e-05	0.000131	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—HMOX1—esophageal cancer	3.56e-05	0.00013	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	3.55e-05	0.000129	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GNG7—esophageal cancer	3.51e-05	0.000128	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.49e-05	0.000127	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KDR—esophageal cancer	3.46e-05	0.000126	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KDR—esophageal cancer	3.45e-05	0.000126	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ABCB1—esophageal cancer	3.42e-05	0.000125	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	3.41e-05	0.000124	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KDR—esophageal cancer	3.4e-05	0.000124	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	3.35e-05	0.000122	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.29e-05	0.00012	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—HMOX1—esophageal cancer	3.27e-05	0.000119	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	3.26e-05	0.000119	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	3.25e-05	0.000118	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	3.2e-05	0.000117	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	3.2e-05	0.000117	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—esophageal cancer	3.14e-05	0.000115	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.13e-05	0.000114	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.1e-05	0.000113	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NOS3—esophageal cancer	3.05e-05	0.000111	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CREBBP—esophageal cancer	2.96e-05	0.000108	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	2.95e-05	0.000107	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ENO1—esophageal cancer	2.93e-05	0.000107	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.93e-05	0.000107	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	2.91e-05	0.000106	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—esophageal cancer	2.9e-05	0.000106	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	2.9e-05	0.000106	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	2.9e-05	0.000106	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PSME1—esophageal cancer	2.89e-05	0.000105	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PSME2—esophageal cancer	2.89e-05	0.000105	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	2.86e-05	0.000104	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	2.85e-05	0.000104	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.78e-05	0.000101	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	2.77e-05	0.000101	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.72e-05	9.93e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOS3—esophageal cancer	2.65e-05	9.65e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOS3—esophageal cancer	2.64e-05	9.62e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	2.6e-05	9.47e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.58e-05	9.42e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—esophageal cancer	2.52e-05	9.2e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	2.52e-05	9.19e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	2.51e-05	9.16e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.49e-05	9.1e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—esophageal cancer	2.48e-05	9.02e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	2.47e-05	9.02e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	2.47e-05	9e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	2.44e-05	8.9e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	2.43e-05	8.86e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.35e-05	8.55e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EP300—esophageal cancer	2.32e-05	8.47e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CREBBP—esophageal cancer	2.28e-05	8.32e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—esophageal cancer	2.19e-05	7.97e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—esophageal cancer	2.18e-05	7.95e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	2.15e-05	7.82e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.14e-05	7.8e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	2.12e-05	7.71e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	2.11e-05	7.69e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CREBBP—esophageal cancer	2.1e-05	7.66e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	2.08e-05	7.57e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.05e-05	7.49e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NOS3—esophageal cancer	2.04e-05	7.45e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—esophageal cancer	2.02e-05	7.38e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EP300—esophageal cancer	2.01e-05	7.34e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EP300—esophageal cancer	2.01e-05	7.32e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.98e-05	7.22e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EP300—esophageal cancer	1.98e-05	7.2e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NOS3—esophageal cancer	1.88e-05	6.86e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.87e-05	6.82e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—esophageal cancer	1.75e-05	6.4e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—esophageal cancer	1.75e-05	6.37e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.72e-05	6.28e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.72e-05	6.27e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	1.72e-05	6.27e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—esophageal cancer	1.72e-05	6.26e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—esophageal cancer	1.71e-05	6.24e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.68e-05	6.14e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—esophageal cancer	1.66e-05	6.06e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—EP300—esophageal cancer	1.56e-05	5.67e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	1.49e-05	5.43e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	1.48e-05	5.41e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	1.46e-05	5.33e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—esophageal cancer	1.44e-05	5.25e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—esophageal cancer	1.44e-05	5.24e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—EP300—esophageal cancer	1.43e-05	5.21e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—esophageal cancer	1.41e-05	5.15e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.37e-05	5.01e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NOS3—esophageal cancer	1.23e-05	4.48e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.15e-05	4.19e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.12e-05	4.1e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.06e-05	3.86e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—EP300—esophageal cancer	9.35e-06	3.41e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—esophageal cancer	6.92e-06	2.52e-05	CbGpPWpGaD
